Testosterone therapy in transmasculine adolescents and young adults produces a significant reduction in fundamental voice frequency (F0) beginning at 2 months and plateauing by 9 months.
Voice quality as measured by cepstral peak prominence smooth (CPPs) initially decreases but shows partial recovery, remaining below baseline at 12 months.
Patient-reported voice-related distress improves over the course of therapy, alongside reduced anxiety levels, indicating psychosocial benefits of hormonal treatment.
